A Comparative Evaluation of the Therapeutic Effects of Adenosine Triphosphate, Coenzyme Q10, Pyridoxine, and Thiamine Pyrophosphate in a Linezolid-Induced Peripheral Neuropathic Pain Model in Rats

ArticleAçık Erişim

Özet

Background/Objectives: Linezolid is an oxazolidinone antibiotic whose prolonged use is associated with peripheral neuropathy, hyperlactatemia, and metabolic acidosis. These adverse effects are primarily linked to the inhibition of mitochondrial protein synthesis, respiratory chain dysfunction, and oxidative stress. Given the central role of impaired energy metabolism and redox imbalance in drug-induced peripheral neuropathy, therapeutic strategies targeting mitochondrial function are of particular interest. Accordingly, this study aimed to comparatively evaluate the effects of adenosine triphosphate (ATP), coenzyme Q10 (CoQ10), pyridoxine, and thiamine pyrophosphate (TPP) on linezolid-induced peripheral neuropathic pain in rats. Methods: Sixty male albino Wistar rats were assigned to ten groups: healthy (HG); ATP-only (ATPG, 5 mg/kg, intraperitoneally); CoQ10-only (CQ10G, 10 mg/kg, orally); pyridoxine-only (PDXG, 50 mg/kg, orally); TPP-only (TPPG, 20 mg/kg, intraperitoneally); linezolid-only (LZDG, 125 mg/kg, orally); linezolid+ATP (ATLG); linezolid+CoQ10 (CQLG); linezolid+pyridoxine (PXLG); and linezolid+TPP (TPLG). Treatments were administered once daily for ATP, CoQ10, and TPP, and twice daily for linezolid and pyridoxine for 14 days. Oxidative stress indices (MDA, tGSH, SOD, CAT) were quantified in the sciatic nerve using ELISA. Serum lactate dehydrogenase (LDH) activity and blood lactate levels were determined to evaluate metabolic disturbances. Mechanical paw withdrawal thresholds were measured using the Randall–Selitto test both before and after treatment. Results: Linezolid significantly reduced paw withdrawal thresholds and induced oxidative stress, antioxidant depletion, increased LDH activity, and hyperlactatemia. Co-treatment with ATP and CoQ10 attenuated oxidative stress but did not significantly improve linezolid-induced reductions in nociceptive thresholds. In contrast, pyridoxine partially alleviated linezolid-induced neuropathic pain and improved biochemical parameters. Notably, TPP exerted the most robust protective effect, preserving nociceptive thresholds and effectively normalizing oxidative stress and metabolic indices. Conclusions: These findings identify TPP as a promising therapeutic strategy for mitigating linezolid-induced peripheral neuropathic pain by targeting mitochondrial energy metabolism and pyruvate–lactate homeostasis. © 2026 by the authors.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/10348Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.3390/ph19020341Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorOzgodek, Habip Burak
dc.contributor.authorInce, Ramazan
dc.contributor.authorKahramanlar, Agah Abdullah
dc.contributor.authorYavuzer, Bulent
dc.contributor.authorSezgin, Esra Tuba
dc.contributor.authorMammadov, Renad
dc.contributor.authorBakan, Nuri
dc.contributor.authorSuleyman, Halis
dc.date.accessioned2026-10-18T20:25:34.790733115Z
dc.date.available2026-10-18T20:25:34.790733115Z
dc.date.issued2026
dc.description.abstractBackground/Objectives: Linezolid is an oxazolidinone antibiotic whose prolonged use is associated with peripheral neuropathy, hyperlactatemia, and metabolic acidosis. These adverse effects are primarily linked to the inhibition of mitochondrial protein synthesis, respiratory chain dysfunction, and oxidative stress. Given the central role of impaired energy metabolism and redox imbalance in drug-induced peripheral neuropathy, therapeutic strategies targeting mitochondrial function are of particular interest. Accordingly, this study aimed to comparatively evaluate the effects of adenosine triphosphate (ATP), coenzyme Q10 (CoQ10), pyridoxine, and thiamine pyrophosphate (TPP) on linezolid-induced peripheral neuropathic pain in rats. Methods: Sixty male albino Wistar rats were assigned to ten groups: healthy (HG); ATP-only (ATPG, 5 mg/kg, intraperitoneally); CoQ10-only (CQ10G, 10 mg/kg, orally); pyridoxine-only (PDXG, 50 mg/kg, orally); TPP-only (TPPG, 20 mg/kg, intraperitoneally); linezolid-only (LZDG, 125 mg/kg, orally); linezolid+ATP (ATLG); linezolid+CoQ10 (CQLG); linezolid+pyridoxine (PXLG); and linezolid+TPP (TPLG). Treatments were administered once daily for ATP, CoQ10, and TPP, and twice daily for linezolid and pyridoxine for 14 days. Oxidative stress indices (MDA, tGSH, SOD, CAT) were quantified in the sciatic nerve using ELISA. Serum lactate dehydrogenase (LDH) activity and blood lactate levels were determined to evaluate metabolic disturbances. Mechanical paw withdrawal thresholds were measured using the Randall–Selitto test both before and after treatment. Results: Linezolid significantly reduced paw withdrawal thresholds and induced oxidative stress, antioxidant depletion, increased LDH activity, and hyperlactatemia. Co-treatment with ATP and CoQ10 attenuated oxidative stress but did not significantly improve linezolid-induced reductions in nociceptive thresholds. In contrast, pyridoxine partially alleviated linezolid-induced neuropathic pain and improved biochemical parameters. Notably, TPP exerted the most robust protective effect, preserving nociceptive thresholds and effectively normalizing oxidative stress and metabolic indices. Conclusions: These findings identify TPP as a promising therapeutic strategy for mitigating linezolid-induced peripheral neuropathic pain by targeting mitochondrial energy metabolism and pyruvate–lactate homeostasis. © 2026 by the authors.
dc.identifier.doi10.3390/ph19020341
dc.identifier.eissn1424-8247
dc.identifier.issn1424-8247
dc.identifier.issue2
dc.identifier.pmcidPMC12944494
dc.identifier.pmid41754881
dc.identifier.scopus2-s2.0-105031064328
dc.identifier.startpage341
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/10348
dc.identifier.volume19
dc.identifier.wosWOS:001700173500001
dc.language.isoen
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)
dc.relation.ispartofPharmaceuticals
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectadenosine triphosphate
dc.subjectcoenzyme Q10
dc.subjectlinezolid
dc.subjectpaw withdrawal threshold
dc.subjectpyridoxine
dc.subjectsciatic nerve
dc.subjectthiamine pyrophosphate
dc.subjectantioxidant
dc.subjectb6vigen
dc.subjectcocarboxylase hydrochloride
dc.subjectglucose
dc.subjectglutathione
dc.subjectlactate dehydrogenase
dc.subjectlactic acid
dc.subjectmalonaldehyde
dc.subjectmitochondrial protein
dc.subjectoxazolidinone derivative
dc.subjectpyrophosphate
dc.subjectsuperoxide dismutase
dc.subjectthiamine
dc.subjectubidecarenone
dc.subjectanimal experiment
dc.subjectanimal tissue
dc.subjectArticle
dc.subjectbody weight
dc.subjectcomparative biology
dc.subjectenergy metabolism
dc.subjecthomeostasis
dc.subjecthyperlactatemia
dc.subjectlactate blood level
dc.titleA Comparative Evaluation of the Therapeutic Effects of Adenosine Triphosphate, Coenzyme Q10, Pyridoxine, and Thiamine Pyrophosphate in a Linezolid-Induced Peripheral Neuropathic Pain Model in Rats
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus3
rdl.citation.wos4
rdl.departmentDepartment of Pharmacology, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan 24100, Turkey. | Anesthesia Program, Vocational School of Health Services, Erzincan Binali Yıldırım University, Erzincan 24036, Turkey. | Department of Medical Biochemistry, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan 24100, Turkey.
rdl.oa.statusgold
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)